THERAPEUTIC EFFICACY AND SAFETY OF LENVATINIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA BEYOND PROGRESSION WITH SORAFENIB

被引：0
|
作者：
Tomonari, Tetsu
Sato, Yasushi
Tanaka, Takahiro
Tanaka, Hironori
Taniguchi, Tatsuya
Okamoto, Koichi
Sogabe, Masahiro
Miyamoto, Hiroshi
Muguruma, Naoki
Takayama, Tetsuji
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1653
引用
收藏
页码：S1145 / S1146
页数：2
相关论文
共 50 条
  • [1] Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
    Tomonari, Tetsu
    Sato, Yasushi
    Tanaka, Hironori
    Mitsuhashi, Takeshi
    Hirao, Akihiro
    Tanaka, Takahiro
    Taniguchi, Tatsuya
    Okamoto, Koichi
    Sogabe, Masahiro
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Takayama, Tetsuji
    JGH OPEN, 2021, 5 (11): : 1275 - 1283
  • [2] Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib
    Kasuya, Kayoko
    Kawamura, Yusuke
    Kobayashi, Masahiro
    Shindoh, Junichi
    Kobayashi, Yuta
    Kajiwara, Akira
    Iritani, Soichi
    Fujiyama, Shunichiro
    Hosaka, Tetsuya
    Saitoh, Satoshi
    Sezaki, Hitomi
    Akuta, Norio
    Suzuki, Fumitaka
    Suzuki, Yoshiyuki
    Ikeda, Kenji
    Arase, Yasuji
    Eguchi, Yuichiro
    Hashimoto, Masaji
    Kumada, Hiromitsu
    INTERNAL MEDICINE, 2021, 60 (03) : 345 - 351
  • [3] Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
    Yano, Shigeki
    Kawaoka, Tomokazu
    Yamasaki, Shintaro
    Johira, Yusuke
    Kosaka, Masanari
    Shirane, Yuki
    Miura, Ryoichi
    Amioka, Kei
    Naruto, Kensuke
    Yamaoka, Kenji
    Fujii, Yasutoshi
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ono, Atsushi
    Nakahara, Takashi
    Murakami, Eisuke
    Miki, Daiki
    Tsuge, Masataka
    Teraoka, Yuji
    Kouno, Hirotaka
    Takaki, Shintaro
    Mori, Nami
    Tsuji, Keiji
    Oka, Shiro
    CANCERS, 2023, 15 (22)
  • [4] Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
    Hiraoka, Atsushi
    Kumada, Takashi
    Tada, Toshifumi
    Ogawa, Chikara
    Tani, Joji
    Fukunishi, Shinya
    Atsukawa, Masanori
    Hirooka, Masashi
    Tsuji, Kunihiko
    Ishikawa, Toru
    Takaguchi, Koichi
    Kariyama, Kazuya
    Itobayashi, Ei
    Tajiri, Kazuto
    Shimada, Noritomo
    Shibata, Hiroshi
    Ochi, Hironori
    Kawata, Kazuhito
    Toyoda, Hidenori
    Ohama, Hideko
    Nouso, Kazuhiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Hayama, Korenobu
    Arai, Taeang
    Imai, Michitaka
    Koizumi, Yohei
    Nakamura, Shinichiro
    Michitaka, Kojiro
    Hiasa, Yoichi
    Kudo, Masatoshi
    GASTROENTEROLOGY REPORT, 2021, 9 (02): : 133 - 138
  • [5] Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma
    Terashima, Takeshi
    Yamashita, Tatsuya
    Takata, Noboru
    Takeda, Yasuhito
    Kido, Hidenori
    Iida, Noriho
    Kitahara, Masaaki
    Shimakami, Tetsuro
    Takatori, Hajime
    Arai, Kuniaki
    Kawaguchi, Kazunori
    Kitamura, Kazuya
    Yamashita, Taro
    Sakai, Yoshio
    Mizukoshi, Eishiro
    Honda, Masao
    Kaneko, Shuichi
    HEPATOLOGY RESEARCH, 2021, 51 (02) : 190 - 200
  • [6] Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma
    Silvia Camera
    Margherita Rimini
    Federico Rossari
    Toshifumi Tada
    Goki Suda
    Shigeo Shimose
    Masatoshi Kudo
    Changhoon Yoo
    Jaekyung Cheon
    Fabian Finkelmeier
    Ho Yeong Lim
    José Presa
    Gianluca Masi
    Francesca Bergamo
    Francesca Salani
    Mariarosaria Marseglia
    Elisabeth Amadeo
    Francesco Vitiello
    Takashi Kumada
    Naoya Sakamoto
    Hideki Iwamoto
    Tomoko Aoki
    Hong Jae Chon
    Vera Himmelsbach
    Massimo Iavarone
    Giuseppe Cabibbo
    Margarida Montes
    Francesco Giuseppe Foschi
    Caterina Vivaldi
    Sara Lonardi
    Takuya Sho
    Takashi Niizeki
    Naoshi Nishida
    Christoph Steup
    Masashi Hirooka
    Kazuya Kariyama
    Joji Tani
    Masanori Atsukawa
    Koichi Takaguchi
    Ei Itobayashi
    Shinya Fukunishi
    Kunihiko Tsuji
    Toru Ishikawa
    Kazuto Tajiri
    Hironori Ochi
    Satoshi Yasuda
    Hidenori Toyoda
    Chikara Ogawa
    Takashi Nishimura
    Takeshi Hatanaka
    Targeted Oncology, 2024, 19 : 29 - 39
  • [7] Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression
    Hiraoka, Atsushi
    Kumada, Takashi
    Hatanaka, Takeshi
    Tada, Toshifumi
    Kariyama, Kazuya
    Tani, Joji
    Fukunishi, Shinya
    Atsukawa, Masanori
    Hirooka, Masashi
    Tsuji, Kunihiko
    Ishikawa, Toru
    Takaguchi, Koichi
    Itobayashi, Ei
    Tajiri, Kazuto
    Shimada, Noritomo
    Shibata, Hiroshi
    Ochi, Hironori
    Kawata, Kazuhito
    Yasuda, Satoshi
    Toyoda, Hidenori
    Chikara, Ogawa
    Tamai, Tsutomu
    Kakizaki, Satoru
    Tojima, Hiroki
    Nagashima, Tamon
    Ueno, Takashi
    Takizawa, Daichi
    Naganuma, Atsushi
    Ohama, Hideko
    Nouso, Kazuhiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Koizumi, Yohei
    Nakamura, Shinichiro
    Joko, Kouji
    Michitaka, Kojiro
    Hiasa, Yoichi
    Kudo, Masatoshi
    HEPATOLOGY RESEARCH, 2021, 51 (08) : 880 - 889
  • [8] Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma
    Camera, Silvia
    Rimini, Margherita
    Rossari, Federico
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Yoo, Changhoon
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Presa, Jose
    Masi, Gianluca
    Bergamo, Francesca
    Salani, Francesca
    Marseglia, Mariarosaria
    Amadeo, Elisabeth
    Vitiello, Francesco
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Chon, Hong Jae
    Himmelsbach, Vera
    Iavarone, Massimo
    Cabibbo, Giuseppe
    Montes, Margarida
    Foschi, Francesco Giuseppe
    Vivaldi, Caterina
    Lonardi, Sara
    Sho, Takuya
    Niizeki, Takashi
    Nishida, Naoshi
    Steup, Christoph
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    TARGETED ONCOLOGY, 2024, 19 (1) : 29 - 39
  • [9] SAFETY AND EFFICACY OF LENVATINIB PLUS REDUCED PEMBROLIZUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Wu, Chi-Jung
    Hung, Ya-Wen
    Lee, Pei-Chang
    Lee, Chieh-Ju
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    HEPATOLOGY, 2020, 72 : 705A - 705A
  • [10] The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond?
    Xie, Feihu
    Feng, Shi
    Sun, Lejia
    Mao, Yilei
    HEPATOBILIARY SURGERY AND NUTRITION, 2018, 7 (03) : 221 - 224
12345